| [1] Hwang ST, Janik JE, Jaffe ES, et al. Mycosis fungoides and Sezary syndrome. Lancet, 2008,371(9616):945-957.
[2] Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood, 2005,105(10):3768-3785.
[3] Oshtory S, Apisarnthanarax N, Gilliam AC, et al. Usefulness of flow cytometry in the diagnosis of mycosis fungoides. J Am Acad Dermatol, 2007,57(3):454-462.
[4] Feng B, Jorgensen JL, Jones D, et al. Flow cytometric detection of peripheral blood involvement by mycosis fungoides and Sezary syndrome using T-cell receptor Vbeta chain antibodies and its application in blood staging. Mod Pathol, 2009.
[5] Bergman R. How useful are T-cell receptor gene rearrangement studies as an adjunct to the histopathologic diagnosis of mycosis fungoides? Am J Dermatopathol, 1999,21(5):498-502.
[6] Chen M, Deng A, Crowson AN, et al. Assessment of T-cell clonality via T-cell receptor-gamma rearrangements in cutaneous T-cell-dominant infiltrates using polymerase chain reaction and single-stranded DNA conformational polymorphism assay. Appl Immunohistochem Mol Morphol, 2004,12(4):373-379.
[7] ����ϼ. ��ʽϸ�����������ٴ����о��е�Ӧ��. �й�ҽѧ������־, 2008,9(1):42��47.
[8] Stetler-Stevenson M. Flow cytometry in lymphoma diagnosis and prognosis: useful? Best Pract Res Clin Haematol, 2003,16(4):583-597.
[9] Vonderheid EC, Bernengo MG, Burg G, et al. Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol, 2002,46(1):95-106.
[10] Harmon CB, Witzig TE, Katzmann JA, et al. Detection of circulating T cells with CD4+CD7- immunophenotype in patients with benign and malignant lymphoproliferative dermatoses. J Am Acad Dermatol, 1996,35(3 Pt 1):404-410.
[11] Bernengo MG, Novelli M, Quaglino P, et al. The relevance of the CD4+ CD26- subset in the identification of circulating Sezary cells. Br J Dermatol, 2001,144(1):125-135.
[12] Laetsch B, Haffner AC, Dobbeling U, et al. CD4 + /CD7- T cell frequency and polymerase chain reaction-based clonality assay correlate with stage in cutaneous T cell lymphomas. J Invest Dermatol, 2000,114(1):107-111.
[13] Sokolowska-Wojdylo M, Wenzel J, Gaffal E, et al. Absence of CD26 expression on skin-homing CLA+ CD4+ T lymphocytes in peripheral blood is a highly sensitive marker for early diagnosis and therapeutic monitoring of patients with Sezary syndrome. Clin Exp Dermatol, 2005,30(6):702-706.
[14] Vonderheid EC. On the diagnosis of erythrodermic cutaneous T-cell lymphoma. J Cutan Pathol, 2006,33 Suppl 1:27-42.
[15] Kelemen K, Guitart J, Kuzel TM, et al. The usefulness of CD26 in flow cytometric analysis of peripheral blood in Sezary syndrome. Am J Clin Pathol, 2008,129(1):146-156.
[16] Fierro MT, Novelli M, Quaglino P, et al. Heterogeneity of circulating CD4+ memory T-cell subsets in erythrodermic patients: CD27 analysis can help to distinguish cutaneous T-cell lymphomas from inflammatory erythroderma. Dermatology, 2008,216(3):213-221.
[17] Edelman J, Meyerson HJ. Diminished CD3 expression is useful for detecting and enumerating Sezary cells. Am J Clin Pathol, 2000,114(3):467-477.
[18] Morice WG, Kimlinger T, Katzmann JA, et al. Flow cytometric assessment of TCR-Vbeta expression in the evaluation of peripheral blood involvement by T-cell lymphoproliferative disorders: a comparison with conventional T-cell immunophenotyping and molecular genetic techniques. Am J Clin Pathol, 2004,121(3):373-383.
[19] Morice WG, Katzmann JA, Pittelkow MR, et al. A comparison of morphologic features, flow cytometry, TCR-Vbeta analysis, and TCR-PCR in qualitative and quantitative assessment of peripheral blood involvement by Sezary syndrome. Am J Clin Pathol, 2006,125(3):364-374.
[20] Washington LT, Huh YO, Powers LC, et al. A stable aberrant immunophenotype characterizes nearly all cases of cutaneous T-cell lymphoma in blood and can be used to monitor response to therapy. BMC Clin Pathol, 2002,2(1):5.
[21] Introcaso CE, Micaily B, Richardson SK, et al. Total skin electron beam therapy may be associated with improvement of peripheral blood disease in Sezary syndrome. J Am Acad Dermatol, 2008,58(4):592-595.
[22] Schwab C, Willers J, Niederer E, et al. The use of anti-T-cell receptor-Vbeta antibodies for the estimation of treatment success and phenotypic characterization of clonal T-cell populations in cutaneous T-cell lymphomas. Br J Haematol, 2002,118(4):1019-1026.
[23] Ferenczi K, Yawalkar N, Jones D, et al. Monitoring the decrease of circulating malignant T cells in cutaneous T-cell lymphoma during photopheresis and interferon therapy. Arch Dermatol, 2003,139(7):909-913
|
